Development of therapeutic-grade small interfering rnas by chemical engineering

Frontiers in Genetics

Volumn 3, Issue AUG, 2012, Pages

  Bramsen, Jesper B ^a   Kjems, Jørgen ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Chemical modification; Immunogenicity; LNA; Off target effect; OMe; RNAi; siRNA; siRNA therapeutic

Indexed keywords

EID: 84875878783     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2012.00154     Document Type: Review

References (254)

1. Abe, N., Abe, H., and Ito, Y. (2007). Dumbbell-shaped nanocircular RNAs for RNA interference. J. Am. Chem. Soc. 129, 15108-1510
2. Abe, N., Abe, H., Nagai, C., Harada, M., Hatakeyama, H., Harashima, H., Ohshiro, T., Nishihara, M., Furukawa, K., Maeda, M., Tsuneda, S., and Ito, Y. (2011). Synthesis, structure, and biological activity of dumbbell-shaped nanocircular RNAs for RNA interference. Bio-conjug. Chem. 22,2082-209
3. Afonin, K. A., Grabow, W. W., Walker, F. M., Bindewald, E., Dobrovolskaia, M. A., Shapiro, B. A., and Jaeger, L. (2011). Design and self-assembly of siRNA-functionalized RNA nanoparticles for use in automated nanomedicine. Nat. Protoc. 6, 2022-203
4. Alexopoulou, L., Holt, A. C., Medzhitov, R., and Flavell, R. A. (2001). Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413, 732-73
5. Allerson, C. R., Sioufi, N., Jarres, R., Prakash, T. P., Naik, N., Berdeja, A., Wanders, L., Griffey, R. H., Swayze, E. E., and Bhat, B. (2005). Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J. Med. Chem. 48, 901-90
6. Amarzguioui, M., Holen, T., Babaie, E., and Prydz, H. (2003). Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 31,589-59
7. Amarzguioui, M., Lundberg, P., Cantin, E., Hagstrom, J., Behlke, M. A., and Rossi, J. J. (2006). Rational design and in vitro and in vivo delivery of dicer substrate siRNA. Nat. Protoc. 1,508-51
8. Amarzguioui, M., and Prydz, H. (2004). An algorithm for selection of functional siRNA sequences. Biochem. Biophys. Res. Commun. 316, 1050-105
9. Armstrong, M. E., Gantier, M., Li, L., Chung, W Y, McCann, A., Baugh, J. A., and Donnelly, S. C. (2008). Small interfering RNAs induce macrophage migration inhibitory factor production and proliferation in breast cancer cells via a double-stranded RNA-dependent protein kinase-dependent mechanism. J. Immunol. 180, 7125-713
10. Arvey, A., Larsson, E., Sander, C., Leslie, C. S., and Marks, D. S. (2010). Target mRNA abundance dilutes microRNA and siRNA activity. Mol. Syst. Biol. 6, 36
11. Bader, A. G., Brown, D., and Winkler, M. (2010). The promise of microRNA replacement therapy. Cancer Res. 70, 7027-703
12. Baek, D., Villen, J., Shin, C., Camargo, F. D., Gygi, S. P., and Bartel, D. P. (2008). The impact of microRNAs on protein output. Nature 455, 64-7
13. Bartlett, D. W., and Davis, M. E. (2007). Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol. Bioeng. 97, 909-92
14. Behlke, M. A. (2006). Progress towards in vivo use of siRNAs. Mol. Ther. 13, 644-67
15. Behlke, M. A. (2008). Chemical modification of siRNAs for in vivo use. Oligonucleotides 18, 305-31
16. Berge, M., Bonnin, P., Sulpice, E., Vilar, J., Allanic, D., Silvestre, J. S., Levy, B. I., Tucker, G. C., Tobelem, G., and Merkulova-Rainon, T. (2010). Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma. Am. J. Pathol. 177, 3192-320
17. Bernstein, E., Caudy, A. A., Hammond, S. M., and Hannon, G. J. (2001). Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409, 363-36
18. Bertrand, J. R., Pottier, M., Vekris, A., Opolon, P., Maksimenko, A., and Malvy, C. (2002). Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun. 296, 1000-100
19. Bian, Y., Zhou, W., Zhao, Y., Li, X., Geng, W., Hao, R., Yang, Q., and Huang, W. (2011). High-dose siRNAs upregulate mouse Eri-1 at both transcription and posttranscription levels. PLoS ONE 6, e26466. doi:10.1371/journal.pone.0026466
20. Birmingham, A., Anderson, E. M., Reynolds, A., Ilsley-Tyree, D., Leake, D., Fedorov, Y., Baskerville, S., Maksimova, E., Robinson, K., Karpilow, J., Marshall, W. S., and Khvorova, A. (2006). 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat. Methods 3, 199-20
21. Blidner, R. A., Hammer, R. P., Lopez, M. J., Robinson, S. O., and Monroe, W. T. (2007). Fully 2'-deoxy-2'-fluoro substituted nucleic acids induce RNA interference in mammalian cell culture. Chem. Biol. Drug Des. 70, 113-12
22. Braasch, D. A., Jensen, S., Liu, Y., Kaur, K., Arar, K., White, M. A., and Corey, D. R. (2003). RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 42, 7967-797
23. Braasch, D. A., Paroo, Z., Constantinescu, A., Ren, G., Oz, O. K., Mason, R. P., and Corey, D. R. (2004). Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg. Med. Chem. Lett. 14, 1139-114
24. Bramsen, J. B., Laursen, M. B., Damgaard, C. K., Lena, S. W., Babu, B. R., Wengel, J., and Kjems, J. (2007). Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res. 35, 5886-589
25. Bramsen, J. B., Laursen, M. B., Nielsen, A. F., Hansen, T. B., Bus, C., Langkjær, N., Babu, B. R., Højland, T., Abramov, M., Van Aerschot, A., Odadzic, D., Smicius, R., Haas, J., Andree, C., Barman, J., Wenska, M., Srivastava, P., Zhou, C., Honcharenko, D., Hess, S., Muller, E., Bobkov, G. V., Mikhailov, S. N., Fava, E., Meyer, T. F., Chattopadhyaya, J., Zerial, M., Engels, J. W., Herdewijn, P., Wengel, J., and Kjems, J. (2009). A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res. 37,2867-288
26. Bramsen, J. B., Pakula, M. M., Hansen, T.B., Bus, C.,Langkjaer,N., Odadzic, D., Smicius, R., Wengel, S. L., Chattopadhyaya, J., Engels, J. W., Herdewijn, P., Wengel, J., and Kjems, J. (2010). A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res. 38, 5761-577
27. Burnett, J. C., and Rossi, J. J. (2012). RNA-based therapeutics: current progress and future prospects. Chem. Biol. 19, 60-7
28. Burnett, J. C., Rossi, J. J., and Tiemann, K. (2011). Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J. 6, 1130-114
29. Capodici, J., Kariko, K., and Weissman, D. (2002). Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J. Immunol. 169,5196-520
30. Cario, E., and Podolsky, D. K. (2000). Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect. Immun. 68, 7010-701
31. Castanotto, D., Sakurai, K., Lingeman, R., Li, H. T., Shively, L., Aagaard, L., Soifer, H., Gatignol, A., Riggs, A., and Rossi, J. J. (2007). Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res. 35, 5154-516
32. Cekaite, L., Furset, G., Hovig, E., and Sioud, M. (2007). Gene expression analysis in blood cells in response to unmodified and 2'-modified siRNAs reveals TLR-dependent and independent effects. J. Mol. Biol. 365, 90-10
33. Chan, C. Y., Carmack, C. S., Long, D. D., Maliyekkel, A., Shao, Y., Roninson, I. B., and Ding, Y (2009). A structural interpretation of the effect of GC-content on efficiency of RNA interference. BMC Bioinformatics 10(Suppl.1),S33.doi:10.1186/1471-2105-10-S1-S33
34. Chang, C. I., Yoo, J. W., Hong, S. W., Lee, S. E., Kang, H. S., Sun, X., Rogoff, H. A., Ban, C., Kim, S., Li, C. J., and Lee, D. K. (2009). Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Mol. Ther. 17, 725-73
35. Chen, P. Y., Weinmann, L., Gaidatzis, D., Pei, Y., Zavolan, M., Tuschl, T., and Meister, G. (2008). Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 14, 263-27
36. Chiu, Y. L., and Rana, T. M. (2002). RNAi in human cells: basic structural and functional features of small interfering RNA. Mol. Cell 10, 549-56
37. Chiu, Y. L., and Rana, T. M. (2003). siRNA function in RNAi: a chemical modification analysis. RNA 9, 1034-104
38. Cho, W. G., Albuquerque, R. J., Kleinman, M. E., Tarallo, V., Greco, A., Nozaki, M., Green, M. G., Baffi, J. Z., Ambati, B. K., De Falco, M., Alexander, J. S., Brunetti, A., De Falco, S., andAmbati,J. (2009).Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc. Natl. Acad. Sci. U.S.A. 106,7137-714
39. Choung, S., Kim, Y. J., Kim, S., Park, H. O., and Choi, Y. C. (2006). Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem. Biophys. Res. Commun. 342, 919-92
40. Chu, C. Y., and Rana, T. M. (2008). Potent RNAi by short RNA triggers. RNA 14, 1714-171
41. Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M. E., Bourke, J., Wells, D. J., Dickson, G., Wood, M. J., Wilton, S. D., Straub, V., Kole, R., Shrewsbury, S. B., Sewry, C., Morgan, J. E., Bushby, K., and Muntoni, F. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378, 595-60
42. Collingwood, M. A., Rose, S. D., Huang, L., Hillier, C., Amarzguioui, M., Wiiger, M. T., Soifer, H. S., Rossi, J. J., and Behlke, M. A. (2008). Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides 18, 187-20
43. Czauderna, F., Fechtner, M., Dames, S., Aygun, H., Klippel, A., Pronk, G. J., Giese, K., and Kaufmann, J. (2003). Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31,2705-271
44. Dahlgren, C., Zhang, H. Y., Du, Q., Grahn, M., Norstedt, G., Wahlestedt, C., and Liang, Z. (2008). Analysis of siRNA specificity on targets with double-nucleotide mismatches. Nucleic Acids Res. 36, e5
45. Dande, P., Prakash, T. P., Sioufi, N., Gaus, H., Jarres, R., Berdeja, A., Swayze, E. E., Griffey, R. H., and Bhat, B. (2006). Improving RNA interference in mammalian cells by 4'-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2' - O-alkyl modifications. J. Med. Chem. 49, 1624-163
46. Davidson, B. L., and McCray, P. B. Jr. (2011). Current prospects for RNA interference-based therapies. Nat Rev. Genet. 12, 329-34
47. Davis, M. E., Zuckerman, J. E., Choi, C. H., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., and Ribas, A. (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464,1067-107
48. Deleavey, G. F., Watts, J. K., Alain, T., Robert, F., Kalota, A., Aishwarya, V., Pelletier, J., Gewirtz, A. M., Sonenberg, N., and Damha, M. J. (2010). Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing. Nucleic Acids Res. 38, 4547-455
49. DeVincenzo, J., Cehelsky, J. E., Alvarez, R., Elbashir, S., Harborth, J., Toudjarska, I., Nechev, L., Murugaiah, V., Van Vliet, A., Vaishnaw, A. K., and Meyers, R. (2008). Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 77,225-23
50. Diebold, S. S., Kaisho, T., Hemmi, H., Akira,S.,andReise Sousa, C. (2004). Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529-153
51. Diebold, S. S., Massacrier, C., Akira, S., Paturel, C., Morel, Y., and Reis e Sousa, C. (2006). Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur. J. Immunol. 36, 3256-326
52. Doench, J. G., Petersen, C. P., and Sharp, P. A. (2003). siRNAs can function as miRNAs. Genes Dev. 17,438-44
53. Doench, J. G., and Sharp, P. A. (2004). Specificity of microRNA target selection in translational repression. GenesDev. 18,504-51
54. Dowler, T., Bergeron, D., Tedeschi, A. L., Paquet, L., Ferrari, N., and Damha, M. J. (2006). Improvements in siRNA properties mediated by 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA). Nucleic Acids Res. 34, 1669-167
55. Du, Q., Thonberg, H., Wang, J., Wahlestedt, C., and Liang, Z. (2005). A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res. 33, 1671-167
56. Dua, P., Yoo, J. W., Kim, S., and Lee, D. K. (2011). Modified siRNA structure with a single nucleotide bulge overcomes conventional siRNA-mediated off-target silencing. Mol. Ther. 19, 1676-168
57. Ebalunode, J. O., Jagun, C., and Zheng, W (2011). Informatics approach to the rational design of siRNA libraries. Methods Mol. Biol. 672, 341-35
58. Eberle, F., Giessler, K., Deck, C., Heeg, K., Peter, M., Richert, C., and Dalpke, A. H. (2008). Modifications in small interfering RNA that separate immunostimulation from RNA interference. J. Immunol. 180, 3229-323
59. Eckstein, F. (2002). Developments in RNA chemistry, a personal view. Biochimie 84, 841-84
60. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. (2001a). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-49
61. Elbashir, S. M., Martinez, J., Patkaniowska, A., Lendeckel, W., and Tuschl, T. (2001b). Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 20, 6877-688
62. Elmen, J., Lindow, M., Schutz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjarn, M., Hansen, H. F., Berger, U., Gullans, S., Kearney, P., Sarnow, P., Straarup, E. M., and Kauppinen, S. (2008). LNA-mediated microRNA silencing in non-human primates. Nature 452, 896-89
63. Elmén, J., Thonberg, H., Ljungberg, K., Frieden, M., Westergaard, M., Xu, Y., Wahren, B., Liang, Z., Ørum, H., Koch, T., and Wahlestedt, C. (2005). Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 33, 439-44
64. Fedorov, Y., Anderson, E. M., Birmingham, A., Reynolds, A., Karpilow, J., Robinson, K., Leake, D., Marshall, W S., and Khvorova, A. (2006). Off-target effects by siRNA can induce toxic phenotype. RNA 12,1188-119
65. Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., and Mello, C. C. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-81
66. Fisher, M., Abramov, M., Van Aerschot, A., Rozenski, J., Dixit, V., Juliano, R. L., and Herdewijn, P. (2009). Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf. Eur. J. Pharmacol. 606, 38-4
67. Fisher, M., Abramov, M., Van Aerschot, A., Xu, D., Juliano, R. L., and Herdewijn, P. (2007). Inhibition of MDR1 expression with altritol-modified siRNAs. Nucleic Acids Res. 35, 1064-107
68. Forsbach, A., Nemorin, J. G., Montino, C., Muller, C., Samulowitz, U., Vicari, A. P., Jurk, M., Mutwiri, G. K., Krieg, A. M., Lipford, G. B., and Vollmer, J. (2008). Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J. Immunol. 180, 3729-373
69. Foster, D. J., Barros, S., Duncan, R., Shaikh, S., Cantley, W., Dell, A., Bulgakova, E., O'Shea, J., Taneja, N., Kuchimanchi, S., Sherrill, C. B., Akinc, A., Hinkle, G., Seila White, A. C., Pang, B., Charisse, K., Meyers, R., Manoharan, M., and Elbashir, S. M. (2012). Comprehensive evaluation of canonical versus dicer-substrate siRNA in vitro and in vivo. RNA 18, 557-56
70. Freier,S.M.,andAltmann,K.H. (1997). The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. Nucleic Acids Res. 25, 4429-444
71. Fucini, R. V., Haringsma, H. J., Deng, P., Flanagan, W M., and Willingham, A. T. (2012). Adenosine modification may be preferred for reducing siRNA immune stimulation. Nucleic Acid Ther. 22,205-21
72. Gantier, M. P., Tong, S., Behlke, M. A., Xu, D., Phipps, S., Foster, P. S., and Williams, B. R. (2008). TLR7 is involved in sequence-specific sensing of single-stranded RNAs in human macrophages. J. Immunol. 180,2117-212
73. Gao, S., Dagnaes-Hansen, F., Nielsen, E. J., Wengel, J., Besenbacher, F., Howard, K. A., and Kjems, J. (2009). The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol. Ther. 17, 1225-123
74. Ge, Q., Dallas, A., Ilves, H., Shorenstein, J., Behlke, M. A., and Johnston, B. H. (2009a). Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs. RNA 16, 118-13
75. Ge, Q., Ilves, H., Dallas, A., Kumar, P., Shorenstein, J., Kazakov, S. A., and Johnston, B. H. (2009b). Minimal-length short hairpin RNAs: the relationship of structure and RNAi activity. RNA 16, 106-11
76. Ghosh, P., Dullea, R., Fischer, J. E., Turi, T. G., Sarver, R. W., Zhang, C., Basu, K., Das, S. K., and Poland, B. W. (2009). Comparing 2-nt 3' overhangs against blunt-ended siR-NAs: a systems biology based study. BMC Genomics 10(Suppl. 1), S17. doi:10.1186/1471-2164-10-S1-S17
77. Glud, S. Z., Bramsen, J. B., Dagnaes-Hansen, F., Wengel, J., Howard, K. A., Nyengaard, J. R., and Kjems, J. (2009). Naked siLNA-mediated gene silencing of lung bronchoepithelium EGFP expression after intravenous administration. Oligonucleotides 19, 163-16
78. Goodchild, A., Nopper, N., King, A., Doan, T., Tanudji, M., Arndt, G. M., Poidinger, M., Rivory, L. P., and Passioura, T. (2009). Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunol. 10,40. doi:10.1186/1471-2172-10-40
79. ;-C-aminomethyl-2'-O-methyl modified small interfering RNAs. J. Org. Chem. 77, 3233-324
80. Grabow, W. W., Zakrevsky, P., Afonin, K. A., Chworos, A., Shapiro, B. A., and Jaeger, L. (2011). Self-assembling RNA nanorings based on RNAI/II inverse kissing complexes. Nano Lett. 11,878-88
81. Grunweller, A., Wyszko, E., Bieber, B., Jahnel, R., Erdmann, V. A., and Kurreck, J. (2003). Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res. 31, 3185-319
82. Guo, H., Ingolia, N. T., Weissman, J. S., and Bartel, D. P. (2010). Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835-84
83. Gupta, N., Fisker, N., Asselin, M. C., Lindholm, M., Rosenbohm, C., Orum, H., Elmen, J., Seidah, N. G., and Straarup, E. M. (2010). Alocked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS ONE 5, e10682. doi:10.1371/journal.pone.0010682
84. Hall, A. H., Wan, J., Shaughnessy, E. E., Ramsay Shaw, B., and Alexander, K. A. (2004). RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res. 32, 5991-600
85. Hall, A. H., Wan, J., Spesock, A., Sergueeva, Z., Shaw, B. R., and Alexander, K. A. (2006). High potency silencing by single-stranded boranophosphate siRNA. Nucleic Acids Res. 34,2773-278
86. Hamada, M., Ohtsuka, T., Kawaida, R., Koizumi, M., Morita, K., Furukawa, H., Imanishi, T., Miyagishi, M., and Taira, K. (2002). Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3'-ends of siRNAs. Anti-sense Nucleic Acid Drug Dev. 12, 301-30
87. Hamm, S., Latz, E., Hangel, D., Muller, T., Yu, P., Golenbock, D., Sparwasser, T., Wagner, H., and Bauer, S. (2009). Alternating 2'- O-ribosemethylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist. Immunobiology 215, 559-56
88. Hammond, S. M., Boettcher, S., Caudy, A. A.,Kobayashi, R., andHannon, G. J. (2001).Argonaute2,alinkbetween genetic and biochemical analyses of RNAi. Science 293, 1146-115
89. Han, Q., Zhang, C., Zhang, J., and Tian, Z. (2011). Involvement of activation of PKR in HBx-siRNA-mediated innate immune effects on HBV inhibition. PLoS ONE 6, e27931. doi:10.1371/journal.pone.0027931
90. Harborth, J., Elbashir, S. M., Vandenburgh, K., Manninga, H., Scaringe, S. A., Weber, K., and Tuschl, T. (2003). Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. 13, 83-10
91. Haupenthal, J., Baehr, C., Kiermayer, S., Zeuzem, S., and Piiper, A. (2006). Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum. Biochem. Pharmacol. 71,702-71
92. Haupenthal, J., Baehr, C., Zeuzem, S., and Piiper, A. (2007). RNAse A-like enzymes in serum inhibit the anti-neoplastic activity of siRNA targeting polo-like kinase 1. Int. J. Cancer 121,206-21
93. Hefner, E., Clark, K., Whitman, C., Behlke, M. A., Rose, S. D., Peek, A. S., and Rubio, T. (2008). Increased potency and longevity of gene silencing using validated dicer substrates. J. Biomol. Tech. 19,231-23
94. Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., and Bauer, S. (2004). Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303, 1526-152
95. Highleyman, L. (1998). FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration. BETA. Higuchi, Y., Kawakami, S., and Hashida, M. (2010). Strategies for in vivo delivery of siRNAs: recent progress. BioDrugs 24, 195-20
96. Hoerter, J. A., and Walter, N. G. (2007). Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum. RNA 13, 1887-189
97. Hogrefe, R. I., Lebedev, A. V., Zon, G., Pirollo, K. F., Rait, A., Zhou, Q., Yu, W., and Chang, E. H. (2006). Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2. Nucleosides Nucleotides Nucleic Acids 25, 889-90
98. Hohjoh, H. (2004). Enhancement of RNAi activity by improved siRNA duplexes. FEBS Lett. 557,193-19
99. Holen, T., Amarzguioui, M., Babaie, E., and Prydz, H. (2003). Similar behaviour of single-strand and double-strand siRNAs suggests they act through a common RNAi pathway. Nucleic Acids Res. 31,2401-240
100. Hong, J., Huang, Y., Li, J., Yi, F., Zheng, J., Huang, H., Wei, N., Shan, Y., An, M., Zhang, H.,Ji,J., Zhang, P., Xi,Z.,Du, Q., and Liang, Z. (2010). Comprehensive analysis of sequence-specific stability of siRNA. FASEB J. 24, 4844-485
101. Hong, J., Qian, Z., Shen, S., Min, T., Tan, C., Xu, J., Zhao, Y., and Huang, W. (2005). High doses of siRNAs induce eri-1 andadar-1 gene expression and reduce the efficiency of RNA interference in the mouse. Biochem. J. 390,675-67
102. Hornung, V., Ellegast, J., Kim, S., Brzozka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K. K., Schlee, M., Endres, S., and Hartmann, G. (2006). 5'-Triphosphate RNA is the ligand for RIG-I. Science 314, 994-99
103. Hornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A., Manoharan, M., Akira, S., De Fougerolles, A., Endres, S., and Hartmann, G. (2005). Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11, 263-27
104. Hornung, V., Rothenfusser, S., Britsch, S., Krug, A., Jahrsdorfer, B., Giese, T., Endres, S., and Hartmann, G. (2002). Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivityto CpG oligodeoxynucleotides. J. Immunol. 168,4531-453
105. Hoshika, S., Minakawa, N., Kamiya, H., Harashima, H., and Matsuda, A. (2005). RNA interference induced by siRNAs modified with 4'-fhioribonucleosides in cultured mammalian cells. FEBS Lett. 579, 3115-311
106. Hoshika, S., Minakawa, N., Shionoya, A., Imada, K., Ogawa, N., and Matsuda, A. (2007). Study of modification pattern-RNAi activity relationships by using siRNAs modified with 4'-thioribonucleosides. Chem-biochem 8, 2133-213
107. Huesken, D., Lange, J., Mickanin, C., Weiler, J., Asselbergs, F., Warner, J., Meloon, B., Engel, S., Rosenberg, A., Cohen, D., Labow, M., Reinhardt, M., Natt, F., and Hall, J. (2005). Design of a genome-wide siRNA library using an artificial neural network. Nat. Biotechnol. 23, 995-100
108. Hutvagner, G., and Zamore, P. D. (2002). A microRNA in a multiple-turnover RNAi enzyme complex. Science 297,2056-206
109. Ichihara, M., Murakumo, Y., Masuda, A., Matsuura, T., Asai, N., Jijiwa, M., Ishida, M., Shinmi, J., Yatsuya, H., Qiao, S., Takahashi, M., and Ohno, K. (2007). Thermodynamic instability of siRNA duplex is a prerequisite for dependable prediction of siRNA activities. Nucleic Acids Res. 35, e12
110. Inaba, S., Nagahara, S., Makita, N., Tarumi, Y., Ishimoto, T., Matsuo, S., Kadomatsu, K., and Takei, Y. (2012). Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals. Mol. Ther. 20, 356-36
111. Iwase, R., Toyama, T., and Nishimori, K. (2007). Solid-phase synthesis of modified RNAs containing amide-linked oligoribonucleosides at their 3'-end and their application to siRNA. Nucleosides Nucleotides Nucleic Acids 26, 1451-145
112. Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., and Linsley, P. S. (2003). Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21, 635-63
113. Jackson, A. L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J., Johnson, J. M., Lim, L., Karpilow, J., Nichols, K., Marshall, W., Khvorova, A., and Linsley, P. S. (2006a). Position-specific chemical modification of siRNAs reduces " off-target" transcript silencing. RNA 12, 1197-120
114. Jackson, A. L., Burchard, J., Schelter, J., Chau, B. N., Cleary, M., Lim, L., and Linsley, P. S. (2006b). Widespread siRNA " off-target" transcript silencing mediated by seed region sequence complementarity. RNA 12, 1179-118
115. Jagla, B., Aulner, N., Kelly, P. D., Song, D., Volchuk, A., Zatorski, A., Shum, D., Mayer, T., De Angelis, D. A., Ouerfelli, O., Rutishauser, U., and Rothman, J. E. (2005). Sequence characteristics of functional siRNAs. RNA 11,864-87
116. Judge, A. D., Bola, G., Lee, A. C., and MacLachlan, I. (2006). Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13, 494-50
117. Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., and MacLachlan, I. (2005). Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23, 457-46
118. Jurk, M., Chikh, G., Schulte, B., Kritzler, A., Richardt-Pargmann, D., Lampron, C., Luu, R., Krieg, A. M., Vicari, A. P., and Vollmer, J. (2011). Immunostimulatory potential of silencing RNAs can be mediated by a non-uridine-rich toll-like receptor 7 motif. Nucleic Acid Ther. 21,201-21
119. Kang, D. C., Gopalkrishnan, R. V., Wu, Q., Jankowsky E., Pyle, A. M., and Fisher, P. B. (2002). mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc. Natl. Acad. Sci. U.S.A. 99, 637-64
120. Kariko, K., Bhuyan, P., Capodici, J., Ni, H., Lubinski, J., Friedman, H., and Weissman, D. (2004). Exogenous siRNA mediates sequence-independent gene suppression by signaling through toll-like receptor 3. Cells Tissues Organs (Print) 177, 132-13
121. Kariko, K., Buckstein, M., Ni, H., and Weissman,D. (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165-17
122. Kennedy, S., Wang, D., and Ruvkun, G. (2004). A conserved siRNA-degrading RNase negatively regulates RNA interference in C.elegans. Nature 427, 645-649.
123. Khan, A. A., Betel, D., Miller, M. L., Sander, C., Leslie, C. S., and Marks, D. S. (2009). Transfection of small RNAs globally perturbs gene regu lation by endogenous microRNAs. Nat. Biotechnol. 27, 549-55
124. Khvorova, A., Reynolds, A., and Jayasena, S. D. (2003). Functional siRNAs and miRNAs exhibit strand bias. Cell 115,209-21
125. Kim, D. H., Behlke, M. A., Rose, S. D., Chang, M. S., Choi, S., and Rossi, J. J. (2005). Synthetic dsRNA dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol. 23, 222-22
126. Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., Albuquerque, R. J. C., Yamasaki, S., Itaya, M., Pan, Y. Z., Appukuttan, B., Gibbs, D., Yang, Z. L., Kariko, K., Ambati, B. K., Wilgus, T. A., Dipietro, L. A., Sakurai, E., Zhang, K., Smith, J. R., Taylor, E. W., and Ambati, J. (2008).Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452, 591-59
127. Klingelhoefer, J. W., Moutsianas, L., and Holmes, C. (2009). Approximate Bayesian feature selection on a large meta-dataset offers novel insights on factors that effect siRNA potency. Bioinformatics 25, 1594-160
128. Kokkinopoulos, I., Jordan, W J., and Ritter, M. A. (2005). Toll-like receptor mRNA expression patterns in human dendritic cells and monocytes. Mol. Immunol. 42, 957-96
129. Koller, E., Propp, S., Murray, H., Lima, W., Bhat, B., Prakash, T. P., Allerson, C. R., Swayze, E. E., Marcusson, E. G., and Dean, N. M. (2006). Competition for RISC binding predicts in vitro potency of siRNA. Nucleic Acids Res. 34, 4467-447
130. Kraynack, B. A., and Baker, B. F. (2006). Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity. RNA 12,163-17
131. Krieg, A. M. (2011). Is RNAI dead Mol. Ther. 19,1001-100
132. Kurreck, J. (2003). Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 270,1628-164
133. Ladunga, I. (2007). More complete gene silencing by fewer siRNAs: transparent optimized design and biophysical signature. Nucleic Acids Res. 35, 433-44
134. Langkjær, N., Pasternak, A., and Wengel, J. (2009). UNA (unlocked nucleic acid): a flexible RNA mimic that allows engineering of nucleic acid duplex stability. Bioorg. Med. Chem. 17, 5420-542
135. Lares, M. R., Rossi, J. J., and Ouellet, D. L. (2010). RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol. 28, 570-57
136. Laursen, M. B., Pakula, M. M., Gao, S., Fluiter, K., Mook, O. R., Baas, F., Langklær, N., Wengel, S. L., Wengel, J., Kjems, J., and Bramsen, J. B. (2010). Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol. Biosyst. 6, 862-87
137. Layzer, J. M., McCaffrey, A. P., Tanner, A. K., Huang, Z., Kay, M. A., and Sullenger, B. A. (2004). In vivo activity of nuclease-resistant siRNAs. RNA 10, 766-77
138. Leachman, S. A., Hickerson, R. P., Schwartz, M. E., Bullough, E. E., Hutcherson, S. L., Boucher, K. M., Hansen, C. D., Eliason, M. J., Srivatsa, G. S., Kornbrust, D. J., Smith, F. J., McLean, W I., Milstone, L. M., and Kaspar,R.L. (2010).First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol. Ther. 18,442-44
139. Ledford, H. (2010). Drug giants turn their backs on RNA interference. Nature 468,48
140. Lee, H. S., Lee, S. N., Joo, C. H., Lee, H., Yoon, S. Y., Kim, Y. K., and Choe, H. (2007). Contributions of 3'-overhang to the dissociation of small interfering RNAs from the PAZ domain: molecular dynamics simulation study. J. Mol. Graph. Model. 25, 784-79
141. Leuschner, P. J., Ameres, S. L., Kueng, S., and Martinez, J. (2006). Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBORep. 7,314-32
142. Li, P., Sergueeva, Z. A., Dobrikov, M., and Shaw, B. R. (2007). Nucleoside and oligonucleoside boranophosphates: chemistry and properties. Chem. Rev. 107,4746-479
143. Li, Z. Y., Mao, H., Kallick, D. A., and Gorenstein, D. G. (2005). The effects of thiophosphate substitutions on native siRNA gene silencing. Biochem. Biophys. Res. Commun. 329,1026-103
144. Lim, D. M., Narasimhan, S., Michaylira, C. Z., and Wang, M. L. (2009). TLR3- mediated NF-{kappa}B signaling in human esophageal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 297, G1172-G118
145. Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., and Johnson, J. M. (2005). Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433,769-77
146. Lima, W. F., Wu, H., Nichols, J. G., Sun, H., Murray, H. M., and Crooke, S. T. (2009). Binding and cleavage specificities of human Argonaute2.J. Biol. Chem. 284,26017-2602
147. Lin, X., Ruan, X., Anderson, M. G., McDowell, J. A., Kroeger, P. E., Fesik, S. W., and Shen, Y. (2005). siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res. 33, 4527-453
148. Lingel, A., Simon, B., Izaurralde, E., and Sattler, M. (2004). Nucleic acid 3'-end recognition by the Argonaute2 PAZ domain. Nat. Struct. Mol. Biol. 11,576-57
149. Ma, J. B., Ye, K., and Patel, D. J. (2004). Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain. Nature 429, 318-32
150. Maiti, M., Nauwelaerts, K., Lescrinier, E., and Herdewijn, P. (2011). Structural and binding study of modified siRNAs with the Argonaute 2 PAZ domain by NMR spectroscopy. Chemistry (Easton) 17, 1519-152
151. Manche, L., Green, S. R., Schmedt, C., and Mathews, M. B. (1992). Interactions between double-stranded RNA regulators and the protein kinase DAI. Mol. Cell. Biol. 12, 5238-524
152. Maniataki, E., and Mourelatos, Z. (2005). A human, ATP-independent, RISC assembly machine fueled by pre-miRNA. Genes Dev. 19, 2979-299
153. Manoharan, M., Akinc, A., Pandey, R. K., Qin, J., Hadwiger, P., John, M., Mills, K., Charisse, K., Maier, M. A., Nechev, L., Greene, E. M., Pallan, P. S., Rozners, E., Rajeev, K. G., and Egli, M. (2011). Unique gene-silencing and structural properties of 2'-fluoro-modified siRNAs. Angew. Chem. 50, 2284-228
154. Marques, J. T., Devosse, T., Wang, D., Zamanian-Daryoush, M., Serbinowski, P., Hartmann, R., Fujita, T., Behlke, M. A., and Williams, B. R. (2006). A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat. Biotechnol. 24, 559-56
155. Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R., and Tuschl, T. (2002). Single-stranded anti-sense siRNAs guide target RNA cleavage in RNAi. Cell 110, 563-57
156. Martinez, J., and Tuschl, T. (2004). RISC is a 5; phosphomonoester-producing RNA endonuclease. Genes Dev. 18,975-98
157. Matranga, C., Tomari, Y., Shin, C., Bartel, D. P., and Zamore, P. D. (2005). Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 123, 607-62
158. Meade, B. R., and Dowdy, S. E (2009). The road to therapeutic RNA interference (RNAi): Tackling the 800 pound siRNA delivery gorilla. Discov. Med. 8, 253-25
159. Meister, G., Landthaler, M., Patkaniowska, A., Dorsett, Y., Teng, G., and Tuschl, T. (2004). Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol. Cell 15, 185-19
160. Melnikova, I. (2007). RNA-based therapies. Nat. Rev. Drug Discov. 6, 863-86
161. Merkel, O. M., Librizzi, D., Pfestroff, A., Schurrat, T., Behe, M., and Kissel, T. (2009). In vivo SPECT and realtime gamma camera imaging of biodistribution and pharmacokinetics of siRNA delivery using an optimized radiolabeling and purification procedure. Bioconjug. Chem. 20, 174-18
162. Minks, M. A., West, D. K., Benvin, S., and Baglioni, C. (1979). Structural requirements of double-stranded RNA for the activation of 2',5'-oligo(A) polymerase and protein kinase of interferon-treated HeLa cells. J. Biol. Chem. 254, 10180-1018
163. Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., and Freier, S. M. (1993). Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268, 14514-1452
164. Mook, O. R., Baas, F., De Wissel, M. B., and Fluiter, K. (2007). Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol. Cancer Ther. 6, 833-84
165. Morrissey, D. V., Blanchard, K., Shaw, L., Jensen, K., Lockridge, J. A., Dickinson, B., McSwiggen, J. A., Vargeese, C., Bowman, K., Shaffer, C. S., Polisky, B. A., and Zinnen, S. (2005a). Activity of stabilized short interfering RNA in a mo use model of hepatitis B virus replication. Hepatology 41, 1349-135
166. Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., Vaish, N., Zinnen, S., Vargeese, C., Bowman, K., Shaffer, C. S., Jeffs, L. B., Judge, A., MacLachlan, I., and Polisky, B. (2005b). Potent and persistent in vivo anti-HBV activity of chemi cally modified siRNAs. Nat. Biotechnol. 23, 1002-100
167. Myers, J. W., Chi, J. T., Gong, D., Schaner, M. E., Brown, P. O., and Ferrell, J. E. (2006). Minimizing off-target effects by using diced siRNAs for RNA interference. J. RNAi Gene Silencing 2, 181-19
168. Myers, J. W., and Ferrell, J. E. (2005). Silencing gene expression with dicer-generated siRNA pools. Methods Mol. Biol. 309,93-19
169. Nallagatla, S. R., and Bevilacqua, P. C. (2008). Nucleoside modifica tions modulate activation of the protein kinase PKR in an RNA structure-specific manner. RNA 14, 1201-121
170. Nanduri, S., Carpick, B. W., Yang, Y., Williams, B. R., and Qin, J. (1998). Structure of the double-stranded RNA-binding domain of the protein kinase PKR reveals the molecular basis of its dsRNA-mediated activation. EMBO J. 17,5458-546
171. Nauwelaerts, K., Fisher, M., Froeyen, M., Lescrinier, E., Aerschot, A. V., Xu, D., Delong, R., Kang, H., Juliano, R. L., and Herdewijn, P. (2007). Structural characterization and biological evaluation of small interfering RNAs containing cyclohexenyl nucleosides. J. Am. Chem. Soc. 129, 9340-934
172. Nishina, K.,Unno,T.,Uno,Y.,Kubodera, T., Kanouchi, T., Mizusawa, H., and Yokota, T. (2008). Efficient in vivo delivery of siRNA to the liver by conjugation of alphatocopherol. Mol. Ther. 16,734-74
173. Nykanen, A., Haley, B., and Zamore, P. D. (2001). ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 107,309-32
174. Ocampo, S. M., Romero, C., Avino, A., Burgueno, J., Gassull, M. A., Bermudez, J., Eritja, R., Fernandez, E., and Perales, J. C. (2012). Functionally enhanced siRNA targeting TNFalpha attenuates DSS-induced colitis and TLR-mediated immunostimulation in mice. Mol. Ther. 20, 382-39
175. Odadzic, D., Bramsen, J. B., Smicius, R., Bus, C., Kjems, J., and Engels, J. W. (2008). Synthesis of 2'-O-modified adenosine building blocks and application for RNA interference. Bioorg. Med. Chem. 16,518-52
176. O'Toole, A. S., Miller, S., and Serra, M. J. (2005). Stability of 3' double nucleotide overhangs that model the 3' ends of siRNA. RNA 11, 512-51
177. Parrish, S., Fleenor, J., Xu, S., Mello, C., and Fire, A. (2000). Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference. Mol. Cell 6, 1077-108
178. Peacock, H., Kannan, A., Beal, P. A., and Burrows, C. J. (2011). Chemical modification of siRNA bases to probe and enhance RNA interference. J. Org. Chem. 76, 7295-730
179. Petersen, M., and Wengel, J. (2003). LNA: a versatile tool for therapeutics andgenomics. TrendsBiotechnol. 21, 74-8
180. Petri, S., Dueck, A., Lehmann, G., Putz, N., Rudel, S., Kremmer, E., and Meister, G. (2011). Increased siRNA duplex stability correlates with reduced off-target and elevated on-target effects. RNA 17, 737-74
181. Petrova Kruglova, N. S., Meschaninova, M. I., Venyaminova, A. G., Zenkova, M. A., Vlassov, V. V., and Chernolovskaya, E. L. (2010). 2'-O-methyl-modified anti-MDR1 fork-siRNA duplexes exhibiting high nuclease resistance and prolonged silencing activity. Oligonucleotides 20, 297-30
182. Pirollo, K. F., Rait, A., Zhou, Q., Hwang, S. H., Dagata, J. A., Zon, G., Hogrefe, R. I., Palchik, G., and Chang, E. H. (2007). Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res. 67,2938-294
183. Potera, C. (2007). Antisense - down, but not out. Nat. Biotechnol. 25, 497-49
184. Pradeepkumar, P. I., Amirkhanov, N. V., and Chattopadhyaya, J. (2003). Anti-sense oligonuclotides with oxetane-constrained cytidine enhance heteroduplex stability, and elicit satisfactory RNase H response as well as showing improved resistance to both exo and endonucleases. Org. Biomol. Chem. 1,81-9
185. Prakash, T. P., Allerson, C. R., Dande, P., Vickers, T. A., Sioufi, N., Jarres, R., Baker, B. F., Swayze, E. E., Griffey, R. H., and Bhat, B. (2005). Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J. Med. Chem. 48, 4247-425
186. Prakash, T. P., Kraynack, B., Baker, B. F., Swayze, E. E., and Bhat, B. (2006). RNA interference by 2',5'-linked nucleic acid duplexes in mammalian cells. Bioorg. Med. Chem. Lett. 16, 3238-324
187. Puthenveetil, S., Whitby, L., Ren, J., Kelnar, K., Krebs, J. F., and Beal, P. A. (2006). Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modification. Nucleic Acids Res. 34, 4900-491
188. Qiu, L., Moreira, A., Kaplan, G., Levitz, R., Wang, J. Y., Xu, C., and Drlica, K. (1998). Degradation of hammerhead ribozymes by human ribonucleases. Mol. Gen. Genet. 258, 352-36
189. Raemdonck, K., Remaut, K., Lucas, B., Sanders, N. N., Demeester, J., and De Smedt, S. C. (2006). In situ analysis of single-stranded and duplex siRNA integrity in living cells. Biochemistry 45, 10614-1062
190. Ranjith-Kumar, C. T., Miller, W., Xiong, J., Russell, W K., Lamb, R., Santos, J., Duffy, K. E., Cleveland, L., Park, M., Bhardwaj, K., Wu, Z., Russell, D. H., Sarisky, R. T., Mbow, M. L., and Kao, C. C. (2007). Biochemical and functional analyses of the human Toll-like receptor 3 ectodomain. J. Biol. Chem. 282, 7668-767
191. Reynolds, A., Anderson, E. M., Vermeulen, A., Fedorov, Y., Robinson, K., Leake, D., Karpilow, J., Marshall, W. S., and Khvorova, A. (2006). Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA 12, 988-99
192. Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W S., and Khvorova,A. (2004). Rational siRNA design for RNA interference. Nat. Biotechnol. 22, 326-33
193. Robbins, M., Judge, A., Ambegia, E., Choi, C., Yaworski, E., Palmer, L., McClintock, K., and MaClachlan, I. (2008). Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum. Gene Ther. 19, 991-99
194. Robbins, M., Judge, A., Liang, L., McClintock, K., Yaworski, E., and MacLachlan,I. (2007).2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol. Ther. 15, 1663-166
195. Rose, S. D., Kim, D. H., Amarzguioui, M., Heidel, J. D., Collingwood, M. A., Davis, M. E., Rossi, J. J., and Behlke, M. A. (2005). Functional polarity is introduced by dicer processing of short substrate RNAs. Nucleic Acids Res. 33,4140-415
196. Sanghvi, Y S. (2011). A status update of modified oligonucleotides for chemotherapeutics applications. Curr. Protoc. Nucleic Acid Chem. Chapter 4, Unit 4 1, 1-2
197. Schmidt, C. (2011). RNAi momentum fizzles as pharma shifts priorities. Nat. Biotechnol. 29, 93-9
198. Schwarz, D. S., Hutvagner, G., Du, T., Xu, Z., Aronin, N., and Zamore, P. D. (2003). Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199-20
199. Schyth, B. D., Bramsen, J. B., Pakula, M. M., Larashati, S., Kjems, J., Wengel, J., and Lorenzen, N. (2012). In vivo screening of modified siRNAs for non-specific antiviral effect in a small fish model: number and localization in the strands are important. Nucleic Acids Res. 40,4653-466
200. Shabalina, S. A., Spiridonov, A. N., and Ogurtsov, A. Y. (2006). Computational models with thermodynamic and composition features improve siRNA design. BMC Bioinformatics 7,65. doi:10.1186/1471-2105-7-65
201. Sheehan, D., Lunstad, B., Yamada, C. M., Stell, B. G., Caruthers, M. H., and Dellinger, D. J. (2003). Biochemical properties of phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides. Nucleic AcidsRes. 31,4109-411
202. Shin, D., Kim, S. I., Park, M., and Kim, M. (2007). Immunostimulatory properties and antiviral activity of modified HBV-specific siR-NAs. Biochem. Biophys. Res. Commun. 364, 436-44
203. Shukla, S., Sumaria, C. S., and Pradeep-kumar, P. I. (2010). Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook. ChemMedChem 5, 328-34
204. Siolas, D., Lerner, C., Burchard, J., Ge, W., Linsley, P. S., Paddison, P. J., Hannon, G. J., and Cleary, M. A. (2005). Synthetic shRNAs as potent RNAi triggers. Nat. Biotechnol. 23, 227-23
205. Sioud, M. (2005). Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J. Mol. Biol. 348, 1079-109
206. Sioud, M. (2006). Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2'-hydroxyl uridines in immune responses. Eur. J. Immunol. 36, 1222-123
207. Sioud, M. (2009). Deciphering the code of innate immunity recognition of siRNAs. Methods Mol. Biol. 487, 41-5
208. Sipa, K., Sochacka, E., Kazmierczak-Baranska, J., Maszewska, M., Janicka, M., Nowak, G., and Nawrot, B. (2007). Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA. RNA 13, 1301-131
209. Sledz, C. A., Holko, M., De Veer, M. J., Silverman, R. H., and Williams, B. R. (2003). Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5, 834-83
210. Song, E., Lee, S. K., Dykxhoorn, D. M., Novina, C., Zhang, D., Crawford, K., Cerny, J., Sharp, P. A., Lieberman, J., Manjunath, N., and Shankar, P. (2003). Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J. Virol. 77, 7174-718
211. Sorrentino, S. (1998). Human extracellular ribonucleases: multiplicity, molecular diversity and catalytic properties of the major RNase types. Cell. Mol. Life Sci. 54, 785-79
212. Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., John, M., Kesavan, V., Lavine, G., Pandey, R. K., Racie, T., Rajeev, K. G., Rohl, I.,Toudjarska, I., Wang, G.,Wuschko, S., Bumcrot, D., Koteliansky, V., Limmer, S., Manoharan, M., and Vornlocher, H. P. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432,173-17
213. Srivastava, P., Barman, J., Pathmasiri, W., Plashkevych, O., Wenska, M., and Chattopadhyaya, J. (2007). Five-and six-membered conformationally locked 2',4'-carbocyclic ribothymidines: synthesis, structure, and biochemical studies. J. Am. Chem. Soc. 129,8362-837
214. Stein, C. A., and Krieg, A. M. (1994). Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res. Dev. 4, 67-6
215. Strapps, W R., Pickering, V., Muiru, G. T., Rice, J., Orsborn, S., Polisky, B. A., Sachs, A., and Bartz, S. R. (2010). The siRNA sequence and guide strand overhangs are determinants of in vivo duration of silencing. Nucleic Acids Res. 38, 4788-479
216. Sun, X., Rogoff, H. A., and Li, C. J. (2008). Asymmetric RNA duplexes mediate RNA interference in mammalian cells. Nat. Biotechnol. 26, 1379-138
217. Swayze, E. E., Siwkowski, A. M., Wancewicz, E. V., Migawa, M. T., Wyrzykiewicz, T. K., Hung, G., Monia, B. P., and Bennett, C. F. (2007). Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 35, 687-70
218. Takabatake, Y., Isaka, Y., Mizui, M., Kawachi, H., Takahara, S., and Imai, E. (2007). Chemically modified siRNA prolonged RNA interference in renal disease. Biochem. Biophys. Res. Commun. 363, 432-43
219. Takahashi, M., Minakawa, N., and Matsuda, A. (2009). Synthesis and characterization of 2'-modified-4'-thioRNA: a comprehensive comparison of nuclease stability. Nucleic AcidsRes. 37, 1353-136
220. Takahashi, M., Nagai, C., Hatakeyama, H., Minakawa, N., Harashima, H., and Matsuda, A. (2012). Intra-cellular stability of 2'-OMe-4'-thioribonucleoside modified siRNA leads to long-term RNAi effect. Nucleic Acids Res. 40, 5787-579
221. Takahasi, K., Yoneyama, M., Nishihori, T., Hirai, R., Kumeta, H., Narita, R., Gale, M. Jr., Inagaki, F., and Fujita, T. (2008). Nonself RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune responses. Mol. Cell 29, 428-44
222. Tanudji, M., Machalek, D., Arndt, G. M., and Rivory, L. (2009). Competition between siRNA duplexes: impact of RISC loading efficiency and comparison between conventional-21 bp and dicer-substrate siRNAs. Oligonucleotides 20, 27-3
223. Taura, M., Suico, M. A., Koyama, K., Komatsu, K., Miyakita, R., Matsumoto, C., Kudo, E., Kariya, R., Goto, H., Kitajima, S., Takahashi, C., Shuto, T., Nakao, M., Okada, S., and Kai, H. (2012). Rb/E2F1 regulates the innate immune receptor Toll-like receptor 3 in epithelial cells. Mol. Cell. Biol. 32,1581-159
224. Threlfall, R. N., Torres, A. G., Krivenko, A., Gait, M. J., and Caruthers, M. H. (2012). Synthesis and biological activity of phosphonoacetate- and thiophosphonoacetatemo dified 2'-O-methyloligoribonucleotides. Org. Biomol. Chem. 10, 746-75
225. Tluk, S., Jurk, M., Forsbach, A., Weeratna, R., Samulowitz, U., Krieg, A. M., Bauer, S., and Vollmer, J. (2009). Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses. Int. Immunol. 21, 607-61
226. Tomari, Y., and Zamore, P. D. (2005). Perspective: machines for RNAi. Genes Dev. 19,517-52
227. Tsui, N. B., Ng, E. K., and Lo, Y M. (2002). Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin. Chem. 48, 1647-165
228. Turner, J. J., Jones, S. W., Moschos, S. A., Lindsay, M. A., and Gait, M. J. (2007). MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. Mol. Biosyst. 3, 43-5
229. Ui-Tei, K., Naito, Y., Takahashi, F., Haraguchi, T., Ohki-Hamazaki, H., Juni, A., Ueda, R., and Saigo, K. (2004). Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res. 32, 936-94
230. Ui-Tei, K., Naito, Y., Zenno, S., Nishi, K., Yamato, K., Takahashi, F., Juni, A., and Saigo, K. (2008). Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res. 36,2136-215
231. Usher, D. A. (1969). On the mechanism of ribonuclease action. Proc. Natl. Acad. Sci. U.S.A. 62, 661-66
232. Vaish, N., Chen, F., Seth, S., Fosnaugh, K., Liu, Y., Adami, R., Brown, T., Chen, Y., Harvie, P., Johns, R., Severson, G., Granger, B., Charmley, P., Houston, M., Templin, M. V., and Polisky, B. (2011). Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs. Nucleic Acids Res. 39, 1823-183
233. van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W S., Aartsma-Rus, A., Bremmer-Bout, M., Den Dunnen, J. T.,Koop, K.,Van Der Kooi, A. J., Goemans, N. M., De Kimpe, S. J., Ekhart, P. F., Venneker, E. H., Platenburg, G. J., Verschuuren, J. J., and Van Ommen, G. J. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med. 357, 2677-268
234. Vert, J. P., Foveau, N., Lajaunie, C., and Vandenbrouck, Y. (2006). An accurate and interpretable model for siRNA efficacy prediction. BMC Bioinformatics 7, 520. doi:10.1186/1471-2105-7-520
235. Vickers, T. A., Lima, W. F., Nichols, J. G., and Crooke, S. T. (2007). Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells. Nucleic AcidsRes. 35,6598-661
236. Volkov, A. A., Kruglova, N. S., Meschaninova, M. I., Venyaminova, A. G., Zenkova, M. A., Vlassov, V.V., and Chernolovskaya, E. L. (2009). Selective protection of nuclease-sensitive sites in siRNA prolongs silencing effect. Oligonucleotides 19, 191-20
237. Wang, L., Huang, C., and Yang, J. Y. (2010). Predicting siRNA potency with random forests and support vector machines. BMC Genomics 11(SUPPL 3), S2. doi:10.1186/1471-2164-11-S3-S2
238. Wang, X., Varma, R. K., Beauchamp, L., Magdaleno, S., and Sendera, T. J. (2009a). Selection of hyperfunctional siRNAs with improved potency and specificity. Nucleic Acids Res. 37,e15
239. Wang, Y., Juranek, S., Li, H., Sheng, G., Wardle, G. S., Tuschl, T., and Patel, D. J. (2009b). Nucleation, propagation and cleavage of target RNAs in Ago silencing complexes. Nature 461, 754-76
240. Wang, Y., Sheng, G., Juranek, S., Tuschl, T., and Patel, D. J. (2008). Structure of the guide-strand-containing argonaute silencing complex. Nature 456,209-21
241. Watts, J. K., Choubdar, N., Sadalapure, K., Robert, F., Wahba, A. S., Pelletier, J., Pinto, B. M., and Damha, M. J. (2007). 2'-Fluoro-4'-fhioarabino-modified oligonucleotides: conformational switches linked to siRNA activity. Nucleic Acids Res. 35, 1441-145
242. Weber, C., Muller, C., Podszuweit, A., Montino, C., Vollmer, J., and Forsbach, A. (2012). Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD 14 (in TLR-mediated effects). Immunology 136, 64-7
243. Wei, J. X., Yang, J., Sun, J. F., Jia, L. T., Zhang, Y., Zhang, H. Z., Li, X., Meng, Y. L., Yao, L. B., and Yang, A. G. (2009). Both strands of siRNA have potential to guide posttranscriptional gene silencing in mammalian cells. PLoS ONE 4, e5382. doi:10.1371/journal.pone.0005382
244. Wengel, J., Petersen, M., Nielsen, K. E., Jensen, G. A., Hakansson, A. E., Kumar, R., Sorensen, M. D., Rajwanshi, V. K., Bryld, T., and Jacobsen, J. P. (2001). LNA (locked nucleic acid) and the diastereoisomeric alpha-l-LNA: conformational tuning and high-affinity recognition of DNA/RNA targets. Nucleosides Nucleotides Nucleic Acids 20, 389-39
245. Wilson, C., and Keefe, A. D. (2006). Building oligonucleotide therapeutics using non-natural chemistries. Curr. Opin. Chem. Biol. 10, 607-61
246. Wu, L., Fan, J., and Belasco, J. G. (2006). MicroRNAs direct rapid deadenylation of mRNA. Proc. Natl. Acad. Sci. U.S.A. 103, 4034-403
247. Yamada, C. M., Dellinger, D. J., and Caruthers, M. H. (2007). Synthesis and biological activity of phosphonocarboxylate DNA. Nucleosides Nucleotides Nucleic Acids 26, 539-54
248. Yang, X., Sierant, M., Janicka, M., Peczek, L., Martinez, C., Hassell, T., Li, N., Li, X., Wang, T., and Nawrot, B. (2012). Gene silencing activity of siRNA molecules containing phosphorodithioate substitutions. ACS Chem. Biol. 7, 1214-122
249. ;-half sequence of the guide strand. Biochem. Biophys. Res. Commun. 367, 78-8
250. Zamanian-Daryoush, M., Marques, J. T., Gantier, M. P., Behlke, M. A., John, M., Rayman, P., Finke, J., and Williams, B. R. (2008). Determinants of cytokine induction by small interfering RNA in human peripheral blood mononuclear cells. J. Interferon Cytokine Res. 28, 221-23
251. Zamecnik, P. C., and Stephenson, M. L. (1978). Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. U.S.A. 75, 280-28
252. Zhang, Z., Weinschenk, T., Guo, K., and Schluesener, H. J. (2006). siRNA binding proteins of microglial cells: PKR is an unanticipated ligand. J. Cell Biochem. 97, 1217-122
253. Zimmer, S., Steinmetz, M., Asdonk, T., Motz, I., Coch, C., Hartmann, E., Barchet, W., Wassmann, S., Hartmann, G., and Nickenig, G. (2011). Activation of endothelial toll-like receptor 3 impairs endothelial function. Circ. Res. 108, 1358-136
254. Zimmermann, T. S.,Lee,A. C.,Akinc,A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., Judge, A. D., Lam, K., McClintock, K., Nechev, L. V., Palmer, L. R., Racie, T., Rohl, I., Seiffert, S., Shanmugam, S., Sood, V., Soutschek, J., Toudjarska, I., Wheat, A. J., Yaworski, E., Zedalis, W., Koteliansky, V., Manoharan, M., Vornlocher, H. P., and MacLachlan, I. (2006). RNAi-mediated gene silencing in non-human primates. Nature 441, 111-11